Living Knowledge · Confidence Timeline

atorvastatin lowers LDL cholesterol in hyperlipidaemia

Scientific confidence changes as new graded, independent evidence accumulates. This timeline shows how the evidence for this claim has evolved — what changed, why it changed, and which scientific dimension moved.

Confidence
76%
Uncertainty 71%–81% (±5%)
Evidence coverage
Substantial77%
38 evidence families18 independent groupsRegulatory standing: noneLast meaningful update: 24 Feb 2020
0%50%100%
supporting no-effect contradicting coverage-only— confidence┄ evidence coverage

What changed, and why

  • Quiet period1 Apr 2020 – 1 May 2026
    No confidence movement
    Coverage 79% → 77%

    20 evidence events retrieved. 20 were coverage-only (on-topic, no readable direction).

  • New contradicting evidence

    Confidence
    77% → 76%
    Uncertainty
    ±5% → ±5%
    Coverage
    78% → 79%

    Confidence decreased by 1 point to 76% after 1 contradictory result was incorporated. Evidence coverage was unchanged at 79%.

  • Coverage-only evidence

    Confidence
    77% → 77%
    Uncertainty
    ±5% → ±5%
    Coverage
    80% → 78%

    Confidence was unchanged at 77% — 1 coverage-only item (on-topic, no readable direction) was retrieved but did not change it. Evidence coverage fell from 80% to 78%.

    • Coverage decreased
  • Quiet period22 Apr 2019 – 31 Jan 2020
    No confidence movement

    5 evidence events retrieved. 5 were coverage-only (on-topic, no readable direction).

  • New supporting evidence

    Confidence
    77% → 77%
    Uncertainty
    ±5% → ±5%
    Coverage
    80% → 80%

    Confidence was unchanged at 77%. Evidence coverage was unchanged at 80%.

  • Quiet period30 Jan 2018 – 10 Oct 2018
    No confidence movement

    5 evidence events retrieved. 5 were coverage-only (on-topic, no readable direction).

  • New supporting evidence

    Confidence
    77% → 77%
    Uncertainty
    ±5% → ±5%
    Coverage
    80% → 80%

    Confidence was unchanged at 77%. Evidence coverage was unchanged at 80%.

    • Coverage increased
  • Quiet period27 Dec 2017 – 27 Dec 2017
    No confidence movement

    1 evidence event retrieved. 1 was coverage-only (on-topic, no readable direction).

  • New supporting evidence

    Confidence
    76% → 77%
    Uncertainty
    ±5% → ±5%
    Coverage
    79% → 80%

    Confidence was unchanged at 77%. Evidence coverage was unchanged at 80%.

  • New well-powered no-effect evidence

    Major change
    Confidence
    80% → 76%
    Uncertainty
    ±5% → ±5%
    Coverage
    79% → 79%

    Confidence decreased by 3 points to 76% after 1 well-powered no-effect result was incorporated. Evidence coverage was unchanged at 79%.

    • Confidence decreased

  • New supporting evidence

    Major change
    Confidence
    79% → 80%
    Uncertainty
    ±5% → ±5%
    Coverage
    78% → 79%

    Confidence increased by 1 point to 80% after 1 independent supporting evidence family was incorporated. Evidence coverage was unchanged at 79%.

    • Confidence increased
  • Quiet period1 Jun 2016 – 1 Jul 2017
    No confidence movement

    7 evidence events retrieved. 7 were coverage-only (on-topic, no readable direction).

  • New supporting evidence

    Confidence
    78% → 79%
    Uncertainty
    ±5% → ±5%
    Coverage
    78% → 78%

    Confidence increased by 1 point to 79% after 1 independent supporting evidence family was incorporated. Evidence coverage was unchanged at 78%.

  • Quiet period1 Dec 2015 – 23 May 2016
    No confidence movement

    3 evidence events retrieved. 3 were coverage-only (on-topic, no readable direction).

  • New supporting evidence

    Confidence
    77% → 78%
    Uncertainty
    ±6% → ±5%
    Coverage
    77% → 78%

    Confidence increased by 1 point to 78% after 1 independent supporting evidence family was incorporated. Evidence coverage was unchanged at 78%.

  • Quiet period1 Jul 2015 – 1 Oct 2015
    No confidence movement

    2 evidence events retrieved. 2 were coverage-only (on-topic, no readable direction).

  • New contradicting evidence

    Major change
    Confidence
    82% → 77%
    Uncertainty
    ±4% → ±6%
    Coverage
    76% → 77%

    Confidence decreased by 5 points to 77% after 1 contradictory result was incorporated. Uncertainty widened from ±4% to ±6%. Evidence coverage was unchanged at 77%.

    • Confidence decreased
    • Uncertainty widened
  • Quiet period9 Jan 2015 – 9 Jan 2015
    No confidence movement
    Coverage 78% → 76%

    1 evidence event retrieved. 1 was coverage-only (on-topic, no readable direction).

  • New supporting evidence

    Confidence
    82% → 82%
    Uncertainty
    ±4% → ±4%
    Coverage
    78% → 78%

    Confidence was unchanged at 82%. Evidence coverage was unchanged at 78%.

  • Coverage-only evidence

    Confidence
    82% → 82%
    Uncertainty
    ±4% → ±4%
    Coverage
    80% → 78%

    Confidence was unchanged at 82% — 1 coverage-only item (on-topic, no readable direction) was retrieved but did not change it. Evidence coverage fell from 80% to 78%.

    • Coverage decreased
  • Quiet period1 Jul 2014 – 1 Nov 2014
    No confidence movement

    5 evidence events retrieved. 5 were coverage-only (on-topic, no readable direction).

  • New supporting evidence

    Major change
    Confidence
    81% → 82%
    Uncertainty
    ±4% → ±4%
    Coverage
    79% → 80%

    Confidence increased by 1 point to 82% after 2 independent supporting evidence families were incorporated. Evidence coverage was unchanged at 80%.

    • Confidence increased
    • Coverage increased
  • Quiet period1 Mar 2014 – 29 May 2014
    No confidence movement

    3 evidence events retrieved. 3 were coverage-only (on-topic, no readable direction).

  • New supporting evidence

    Confidence
    80% → 81%
    Uncertainty
    ±5% → ±4%
    Coverage
    79% → 79%

    Confidence was unchanged at 81%. Evidence coverage was unchanged at 79%.

  • Quiet period4 Dec 2013 – 4 Dec 2013
    No confidence movement

    1 evidence event retrieved. 1 was coverage-only (on-topic, no readable direction).

  • New supporting evidence

    Major change
    Confidence
    79% → 80%
    Uncertainty
    ±5% → ±5%
    Coverage
    78% → 79%

    Confidence increased by 2 points to 80% after 1 independent supporting evidence family was incorporated. Evidence coverage was unchanged at 79%.

    • Confidence increased

  • New supporting evidence

    Confidence
    79% → 79%
    Uncertainty
    ±5% → ±5%
    Coverage
    77% → 78%

    Confidence was unchanged at 79%. Evidence coverage was unchanged at 78%.

  • Quiet period1 Jun 2013 – 1 Aug 2013
    No confidence movement

    5 evidence events retrieved. 5 were coverage-only (on-topic, no readable direction).

  • New supporting evidence

    Confidence
    79% → 79%
    Uncertainty
    ±5% → ±5%
    Coverage
    77% → 77%

    Confidence was unchanged at 79%. Evidence coverage was unchanged at 77%.

  • Quiet period1 Sep 2012 – 1 Sep 2012
    No confidence movement
    Coverage 79% → 77%

    2 evidence events retrieved. 2 were coverage-only (on-topic, no readable direction).

  • Coverage-only evidence

    Confidence
    79% → 79%
    Uncertainty
    ±5% → ±5%
    Coverage
    82% → 79%

    Confidence was unchanged at 79% — 1 coverage-only item (on-topic, no readable direction) was retrieved but did not change it. Evidence coverage fell from 82% to 79%.

    • Coverage decreased
  • Quiet period1 Jul 2012 – 1 Jul 2012
    No confidence movement

    1 evidence event retrieved. 1 was coverage-only (on-topic, no readable direction).

  • New well-powered no-effect evidence

    Major change
    Confidence
    81% → 79%
    Uncertainty
    ±5% → ±5%
    Coverage
    81% → 82%

    Confidence decreased by 3 points to 79% after 1 well-powered no-effect result was incorporated. Evidence coverage was unchanged at 82%.

    • Confidence decreased

  • New well-powered no-effect evidence

    Major change
    Confidence
    87% → 81%
    Uncertainty
    ±5% → ±5%
    Coverage
    81% → 81%

    Confidence decreased by 6 points to 81% after 1 well-powered no-effect result was incorporated. Evidence coverage was unchanged at 81%.

    • Confidence decreased
  • Quiet period1 Jan 2012 – 28 Mar 2012
    No confidence movement
    Coverage 84% → 81%

    5 evidence events retrieved. 5 were coverage-only (on-topic, no readable direction).

  • New supporting evidence

    Confidence
    86% → 87%
    Uncertainty
    ±6% → ±5%
    Coverage
    83% → 84%

    Confidence increased by 1 point to 87% after 1 independent supporting evidence family was incorporated. Evidence coverage was unchanged at 84%.

  • Quiet period13 Sep 2011 – 1 Nov 2011
    No confidence movement
    Coverage 91% → 83%

    3 evidence events retrieved. 3 were coverage-only (on-topic, no readable direction).

  • New supporting evidence

    Major change
    Confidence
    85% → 86%
    Uncertainty
    ±6% → ±6%
    Coverage
    90% → 91%

    Confidence increased by 1 point to 86% after 1 independent supporting evidence family was incorporated. Evidence coverage was unchanged at 91%.

    • Confidence increased

  • New contradicting evidence

    Major change
    Confidence
    89% → 85%
    Uncertainty
    ±5% → ±6%
    Coverage
    90% → 90%

    Confidence decreased by 4 points to 85% after 1 contradictory result was incorporated. Evidence coverage was unchanged at 90%.

    • Confidence decreased

  • New supporting evidence

    Confidence
    88% → 89%
    Uncertainty
    ±6% → ±5%
    Coverage
    89% → 90%

    Confidence increased by 1 point to 89% after 1 independent supporting evidence family was incorporated. Evidence coverage was unchanged at 90%.

  • Quiet period1 Feb 2011 – 1 May 2011
    No confidence movement

    3 evidence events retrieved. 3 were coverage-only (on-topic, no readable direction).

  • New supporting evidence

    Major change
    Confidence
    87% → 88%
    Uncertainty
    ±6% → ±6%
    Coverage
    89% → 89%

    Confidence increased by 1 point to 88% after 1 independent supporting evidence family was incorporated. Evidence coverage was unchanged at 89%.

    • Confidence increased

  • New supporting evidence

    Confidence
    87% → 87%
    Uncertainty
    ±6% → ±6%
    Coverage
    88% → 89%

    Confidence was unchanged at 87%. Evidence coverage was unchanged at 89%.

  • New supporting evidence

    Confidence
    86% → 87%
    Uncertainty
    ±6% → ±6%
    Coverage
    88% → 88%

    Confidence increased by 1 point to 87% after 1 independent supporting evidence family was incorporated. Evidence coverage was unchanged at 88%.

  • Quiet period1 Jun 2010 – 1 Jun 2010
    No confidence movement

    1 evidence event retrieved. 1 was coverage-only (on-topic, no readable direction).

  • New supporting evidence

    Confidence
    86% → 86%
    Uncertainty
    ±6% → ±6%
    Coverage
    87% → 88%

    Confidence was unchanged at 86%. Evidence coverage was unchanged at 88%.

  • Quiet period1 Feb 2010 – 1 Feb 2010
    No confidence movement

    1 evidence event retrieved. 1 was coverage-only (on-topic, no readable direction).

  • New supporting evidence

    Confidence
    85% → 86%
    Uncertainty
    ±7% → ±6%
    Coverage
    87% → 87%

    Confidence increased by 1 point to 86% after 1 independent supporting evidence family was incorporated. Evidence coverage was unchanged at 87%.

  • Quiet period1 Aug 2009 – 24 Dec 2009
    No confidence movement
    Coverage 93% → 87%

    4 evidence events retrieved. 4 were coverage-only (on-topic, no readable direction).

  • New supporting evidence

    Confidence
    85% → 85%
    Uncertainty
    ±7% → ±7%
    Coverage
    92% → 93%

    Confidence increased by 1 point to 85% after 1 independent supporting evidence family was incorporated. Evidence coverage was unchanged at 93%.

  • Quiet period1 Jun 2009 – 1 Jun 2009
    No confidence movement

    3 evidence events retrieved. 3 were coverage-only (on-topic, no readable direction).

  • New supporting evidence

    Confidence
    84% → 85%
    Uncertainty
    ±7% → ±7%
    Coverage
    92% → 92%

    Confidence was unchanged at 85%. Evidence coverage was unchanged at 92%.

  • Quiet period1 Apr 2009 – 1 Apr 2009
    No confidence movement

    1 evidence event retrieved. 1 was coverage-only (on-topic, no readable direction).

  • New supporting evidence

    Confidence
    84% → 84%
    Uncertainty
    ±7% → ±7%
    Coverage
    92% → 92%

    Confidence was unchanged at 84%. Evidence coverage was unchanged at 92%.

  • New supporting evidence

    Confidence
    83% → 84%
    Uncertainty
    ±8% → ±7%
    Coverage
    91% → 92%

    Confidence increased by 1 point to 84% after 1 independent supporting evidence family was incorporated. Evidence coverage was unchanged at 92%.

  • Quiet period1 Dec 2008 – 1 Dec 2008
    No confidence movement

    2 evidence events retrieved. 2 were coverage-only (on-topic, no readable direction).

  • New supporting evidence

    Major change
    Confidence
    77% → 83%
    Uncertainty
    ±10% → ±8%
    Coverage
    89% → 91%

    Confidence increased by 6 points to 83% after 3 independent supporting evidence families were incorporated. Uncertainty narrowed from ±10% to ±8%. Evidence coverage rose from 89% to 91%.

    • Confidence increased
    • Uncertainty narrowed
    • Coverage increased

  • New supporting evidence

    Major change
    Confidence
    74% → 77%
    Uncertainty
    ±12% → ±10%
    Coverage
    88% → 89%

    Confidence increased by 3 points to 77% after 1 independent supporting evidence family was incorporated. Uncertainty narrowed from ±12% to ±10%. Evidence coverage rose from 88% to 89%.

    • Confidence increased
    • Uncertainty narrowed
    • Coverage increased
  • Quiet period1 Aug 2008 – 1 Aug 2008
    No confidence movement

    2 evidence events retrieved. 2 were coverage-only (on-topic, no readable direction).

  • New supporting evidence

    Major change
    Confidence
    70% → 74%
    Uncertainty
    ±13% → ±12%
    Coverage
    88% → 88%

    Confidence increased by 4 points to 74% after 1 independent supporting evidence family was incorporated. Uncertainty narrowed from ±13% to ±12%. Evidence coverage was unchanged at 88%.

    • Confidence increased
    • Uncertainty narrowed
  • Quiet period1 May 2008 – 1 May 2008
    No confidence movement

    1 evidence event retrieved. 1 was coverage-only (on-topic, no readable direction).

  • New supporting evidence

    Major change
    Confidence
    69% → 70%
    Uncertainty
    ±14% → ±13%
    Coverage
    86% → 88%

    Confidence increased by 1 point to 70% after 1 independent supporting evidence family was incorporated. Evidence coverage rose from 86% to 88%.

    • Confidence increased
    • Coverage increased

  • New supporting evidence

    Major change
    Confidence
    67% → 69%
    Uncertainty
    ±15% → ±14%
    Coverage
    83% → 86%

    Confidence increased by 2 points to 69% after 1 independent supporting evidence family was incorporated. Uncertainty narrowed from ±15% to ±14%. Evidence coverage rose from 83% to 86%.

    • Confidence increased
    • Uncertainty narrowed
    • Coverage increased

  • New supporting evidence

    Major change
    Confidence
    64% → 67%
    Uncertainty
    ±16% → ±15%
    Coverage
    83% → 83%

    Confidence increased by 3 points to 67% after 1 independent supporting evidence family was incorporated. Uncertainty narrowed from ±16% to ±15%. Evidence coverage was unchanged at 83%.

    • Confidence increased
    • Uncertainty narrowed
  • Quiet period1 Nov 2007 – 1 Nov 2007
    No confidence movement

    1 evidence event retrieved. 1 was coverage-only (on-topic, no readable direction).

  • New supporting evidence

    Major change
    Confidence
    57% → 64%
    Uncertainty
    ±19% → ±16%
    Coverage
    80% → 83%

    Confidence increased by 7 points to 64% after 1 independent supporting evidence family was incorporated. Uncertainty narrowed from ±19% to ±16%. Evidence coverage rose from 80% to 83%.

    • Confidence increased
    • Uncertainty narrowed
    • Coverage increased
  • Quiet period1 Sep 2007 – 1 Sep 2007
    No confidence movement

    2 evidence events retrieved. 2 were coverage-only (on-topic, no readable direction).

  • New supporting evidence

    Major change
    Confidence
    52% → 57%
    Uncertainty
    ±21% → ±19%
    Coverage
    75% → 80%

    Confidence increased by 5 points to 57% after 1 independent supporting evidence family was incorporated. Uncertainty narrowed from ±21% to ±19%. Evidence coverage rose from 75% to 80%.

    • Confidence increased
    • Uncertainty narrowed
    • Coverage increased
  • Quiet period1 Apr 2007 – 1 May 2007
    No confidence movement

    2 evidence events retrieved. 2 were coverage-only (on-topic, no readable direction).

  • New supporting evidence

    Major change
    Confidence
    39% → 52%
    Uncertainty
    ±26% → ±21%
    Coverage
    67% → 75%

    Confidence increased by 13 points to 52% after 1 independent supporting evidence family was incorporated. Uncertainty narrowed from ±26% to ±21%. Evidence coverage rose from 67% to 75%.

    • Confidence increased
    • Uncertainty narrowed
    • Coverage increased
  • Quiet period1 Dec 2006 – 1 Dec 2006
    No confidence movement

    1 evidence event retrieved. 1 was coverage-only (on-topic, no readable direction).

  • New supporting evidence

    Major change
    Confidence
    16% → 39%
    Uncertainty
    ±43% → ±26%
    Coverage
    50% → 67%

    Confidence increased by 22 points to 39% after 1 independent supporting evidence family was incorporated. Uncertainty narrowed from ±43% to ±26%. Evidence coverage rose from 50% to 67%.

    • Confidence increased
    • Uncertainty narrowed
    • Coverage increased

  • Coverage-only evidence

    Confidence
    16% → 16%
    Uncertainty
    ±43% → ±43%
    Coverage
    100% → 50%

    Confidence was unchanged at 16% — 1 coverage-only item (on-topic, no readable direction) was retrieved but did not change it. Evidence coverage fell from 100% to 50%.

    • Coverage decreased
  • Quiet period1 Apr 2004 – 1 Sep 2006
    No confidence movement

    27 evidence events retrieved. 27 were coverage-only (on-topic, no readable direction).

  • New supporting evidence

    Major change
    Confidence
    0% → 16%
    Uncertainty
    ±45% → ±43%
    Coverage
    100%

    Confidence increased by 16 points to 16% after 1 independent supporting evidence family was incorporated. Uncertainty narrowed from ±45% to ±43%.

    • Confidence increased
    • Uncertainty narrowed
  • Quiet period24 May 2001 – 1 Mar 2004
    No confidence movement

    11 evidence events retrieved. 11 were coverage-only (on-topic, no readable direction).

  • Coverage-only evidence

    Confidence
    0% → 0%
    Uncertainty
    ±45% → ±45%

    Confidence for this claim was first established at 0% from 1 coverage-only item (on-topic, no readable direction).

View all evidence · 196 items in the ledger
  • trialNCT00004466 — Pilot Study of Atorvastatin in Children With Chronic Hyperlipidemia SeneutralNo posted results — existence/phase are not direction.
  • trialNCT03884452 — A Phase III Efficacy And Safety Study of Ezetimibe (SCH58235) 10 mg inneutralNo posted results — existence/phase are not direction.
  • trialNCT03867110 — A Phase 3, Double-Blind Efficacy and Safety Study of Ezetimibe (SCH 58neutralNo posted results — existence/phase are not direction.
  • trialNCT03867318 — A Phase III Double-Blind Efficacy and Safety of Ezetimibe (SCH 58235) neutralNo posted results — existence/phase are not direction.
  • trialNCT00392717 — Effect of Atorvastatin and Fish Oils on Lipoprotein Metabolism in ViscneutralNo posted results — existence/phase are not direction.
  • trialNCT03882996 — Long-Term, Open-Label, Safety and Tolerability Study of Ezetimibe (SCHneutralNo posted results — existence/phase are not direction.
  • trialNCT02591836 — An 8-Week, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging neutralNo posted results — existence/phase are not direction.
  • trialNCT03885921 — Long-Term, Open-Label, Safety and Tolerability Study of SCH 58235 in AneutralNo posted results — existence/phase are not direction.
  • trialNCT00442325 — ACTFAST (2): Achieve Cholesterol Targets Fast With Atorvastatin StratineutralNo posted results — existence/phase are not direction.
  • trialNCT00442845 — ACTFAST: Achieve Cholesterol Targets Fast With Atorvastatin StratifiedneutralNo posted results — existence/phase are not direction.
  • trialNCT00644670 — A Multicenter, Twelve-Week Treatment, Single-Step Titration, Open-LabeneutralNo posted results — existence/phase are not direction.
  • trialNCT00653744 — A 6-Week, Randomized, Open-Label, Comparative Study to Evaluate the EfneutralNo posted results — existence/phase are not direction.
  • paperIntensive versus moderate lipid lowering with statins after acute coronary syndromes.supportsEffect reported but bounded (subgroup / regain / caveat) in the conclusion.
  • trialNCT00647543 — A Multicenter, Eight-Week Treatment, Single-Step Titration, Open-LabelneutralNo posted results — existence/phase are not direction.
  • trialNCT00329173 — A 6-Week Open-Label, Randomised, Multicentre, Phase IIIb, Parallel-GroneutralNo posted results — existence/phase are not direction.
  • trialNCT00653796 — SCH 58235: A Multicentre, Randomised, Parallel Group, Placebo-ControllneutralNo posted results — existence/phase are not direction.
  • trialNCT00653588 — A 26-Week, Double Blind, Randomised, Multi-Centre, Phase IIIb, ParalleneutralNo posted results — existence/phase are not direction.
  • trialNCT00654173 — A 12-Week, Randomized, Open-Label, 3 Arm Parallel Group, Multicenter, neutralNo posted results — existence/phase are not direction.
  • trialNCT00654407 — An Open Label, Randomized, Multi-Center, Phase IIIB, Parallel Group SwneutralNo posted results — existence/phase are not direction.
  • trialNCT00640549 — Impact of Atorvastatin on the Distribution, Composition, and MetabolisneutralNo posted results — existence/phase are not direction.
  • trialNCT00645424 — A Randomized, 12-Week, Open Labeled Study To Evaluate The Efficacy AndneutralNo posted results — existence/phase are not direction.
  • trialNCT00654537 — A 6 Week Open Label, Dose Comparison Study to Evaluate the Safety and neutralNo posted results — existence/phase are not direction.
  • trialNCT00650689 — A Multicenter, Randomized, Parallel Groups, Placebo-controlled Study CneutralNo posted results — existence/phase are not direction.
  • trialNCT00645151 — A Multicenter, Eight-Week Treatment, Single Step Titration, Open-LabelneutralNo posted results — existence/phase are not direction.
  • trialNCT00653965 — A 6-Week, Randomized, Open-Label, Comparative Study to Evaluate the EfneutralNo posted results — existence/phase are not direction.
  • trialNCT00864643 — A Double-Blind, Randomized Study to Evaluate the Efficacy and Safety oneutralNo posted results — existence/phase are not direction.
  • trialNCT00644709 — A Multicenter, Open-Label Extension Study Of High-Risk Hyperlipidemic neutralNo posted results — existence/phase are not direction.
  • trialNCT00654225 — A 6-Week, Randomized,Open-Label, Comparative Study to Evaluate the EffneutralNo posted results — existence/phase are not direction.
  • trialNCT00079638 — Comparative Efficacy Evaluation of Lipid Levels When Treated With NiasneutralNo posted results — existence/phase are not direction.
  • trialNCT00150371 — A Multicenter, 12 Week Treatment Single Step Titration Open-Label StudneutralNo posted results — existence/phase are not direction.
  • trialNCT00163202 — A Multicenter, Randomized Double-Blind Study Comparing The PleiotropicneutralNo posted results — existence/phase are not direction.
  • trialNCT00163150 — Lacunar-Brain Infarction Cerebral Hyperactivity And Atorvastatin TrialneutralNo posted results — existence/phase are not direction.
  • trialNCT00174330 — A Multi-Center, Randomized, Open-Label Study To Evaluate Efficacy And neutralNo posted results — existence/phase are not direction.
  • trialNCT00134485 — Phase 3, Multi-Center, Double-Blind, Randomized, Parallel Group, StudyneutralNo posted results — existence/phase are not direction.
  • trialNCT00329069 — Vascular Endothelial Receptor Activity in Patients With Coronary ArterneutralNo posted results — existence/phase are not direction.
  • trialNCT00138762 — A Phase 3, Double Blind, Placebo-Controlled, Randomized, Parallel GrouneutralNo posted results — existence/phase are not direction.
  • trialNCT00143676 — A Double-blind, Randomized Placebo-controlled Study to Evaluate the EfneutralNo posted results — existence/phase are not direction.
  • trialNCT00133380 — PPAR Alpha (LY518674): A Phase 2 Study of the Combinatorial Effect of neutralNo posted results — existence/phase are not direction.
  • trialNCT00134173 — Phase 3, Multi-Center, Double-Blind, Randomized, Parallel Group, CoronneutralNo posted results — existence/phase are not direction.
  • trialNCT00137462 — A Phase 3, Double-Blind, Randomized, Multisite Trial Of The Efficacy, neutralNo posted results — existence/phase are not direction.
  • trialNCT00319449 — A Single Center, Randomized, Parallel Groups, Placebo-Controlled StudyneutralResults posted but no readable target outcome — coverage only.
  • trialNCT00136981 — Phase 3 Multi-Center, Double-Blind, Randomized, Parallel Group, CarotineutralNo posted results — existence/phase are not direction.
  • trialNCT00249249 — Study of Pitavastatin 2 mg vs. Atorvastatin 10 mg and Pitavastatin 4 msupportsStructured CT.gov primary outcome 'Percent Change From Baseline Low Density Lipoprotein-cholesterol (LDL-C) at Week 12': drug arm -38.76% (vs an active comparator, not placebo).
  • trialNCT00134238 — Phase 3 Multi-Center, Double-Blind, Randomized, Parallel Group, CarotineutralNo posted results — existence/phase are not direction.
  • trialNCT00300469 — A Multicenter, Randomized, Double-Blind, Prospective Study Comparing tsupportsStructured CT.gov primary outcome 'Mean Percent Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline to Final Visit': drug arm -33.7% (vs an active comparator, not placebo).
  • trialNCT00141141 — A Phase IV, Multicenter, Randomized, Open Label Study To Evaluate The neutralNo posted results — existence/phase are not direction.
  • trialNCT00487994 — A Double-Blind, Randomized, Parallel Group Study to Evaluate the SafetneutralNo posted results — existence/phase are not direction.
  • trialNCT00309751 — Study of Pitavastatin Vs. Atorvastatin (Following Up-Titration) in PatsupportsStructured CT.gov primary outcome 'Percent Change From Baseline Low Density Lipoprotein Cholesterol (LDL-C)': drug arm -43.25% (vs an active comparator, not placebo).
  • trialNCT00157924 — A Multicenter, Randomized, Open-label Study to Evaluate the Lipid-AlteneutralNo posted results — existence/phase are not direction.
  • trialNCT00665834 — Comparison of the Effect Noted in The Apo/Apo-1 Ratio Using RosuvastatneutralNo posted results — existence/phase are not direction.
  • trialNCT00166504 — A Multicenter, Randomized, Open-label Study to Evaluate the Lipid-AltesupportsStructured CT.gov primary outcome 'LDL-C Lowering Efficacy': drug arm -41% (vs an active comparator, not placebo).
  • trialNCT00844402 — Safety and Efficacy of Long-Term Treatment With Atorvastatin in PatienneutralNo posted results — existence/phase are not direction.
  • trialNCT00427960 — A Phase IV, 6-week, Randomised, Double-blind, Multicentre, Parallel GrneutralResults posted but no readable target outcome — coverage only.
  • trialNCT00465088 — SUPREME: A 12-Week, Open-Label, Multicenter Study to Compare the LipidsupportsStructured CT.gov secondary outcome 'Percent Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline to Week 12': drug arm -46% (vs an active comparator, not placebo).
  • trialNCT00242944 — Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary SyneutralNo posted results — existence/phase are not direction.
  • trialNCT00276484 — A Multicenter, Rand., Double-Blind, Titration Study to Evaluate & CompsupportsStructured CT.gov primary outcome 'Percent Change From Baseline to Week 6 in Low-Density Lipoprotein (LDL)-C': drug arm -27.4% (vs an active comparator, not placebo).
  • trialNCT00344370 — Double-Blind, Follow-On Study of Pitavastatin (4 mg) Versus AtorvastatsupportsStructured CT.gov secondary outcome 'Percent Change From Baseline in LDL-C': drug arm -41.43% (vs an active comparator, not placebo).
  • trialNCT00540293 — A Multicenter, Eight-Week Treatment, Single-Step Titration Open-Label neutralResults posted but no readable target outcome — coverage only.
  • trialNCT00504829 — A 12-Week, Multi-Center, Double-Blind, Randomized, Parallel-Group StudsupportsStructured CT.gov secondary outcome 'Percent Changes From Baseline to End-of-treatment in Non-HDL, HDL and LDL Cholesterol by LCP-AtorFen Versus Fenofibrate Monotherapy': drug arm -44.8% (vs an active comparator, not placebo).
  • trialNCT00362934 — A Multicenter, Double-Blind, Randomized, Forced-Titration Study to ComneutralNo posted results — existence/phase are not direction.
  • trialNCT00701883 — Multicenter Randomized Double-Blind Placebo and Active Comparator ContneutralNo posted results — existence/phase are not direction.
  • trialNCT00690443 — A Randomized, Double Blind Comparator-controlled, Parallel-group StudysupportsStructured CT.gov primary outcome 'Percent Change in LDL-C After 8 Weeks of Therapy': drug arm -39.6% (vs an active comparator, not placebo).
  • trialNCT00917579 — An Open Label, Randomized, Single Dose, Two-Way Crossover BioequivalenneutralResults posted but no readable target outcome — coverage only.
  • trialNCT00917644 — An Open Label, Randomized, Single Dose, Two-Way Crossover BioequivalenneutralResults posted but no readable target outcome — coverage only.
  • trialNCT00418834 — A Multicenter, Randomized, Double-Blind, Parallel Arm, 12-Week Study tneutralResults posted but no readable target outcome — coverage only.
  • trialNCT00474240 — A Randomized, Double-blind, Placebo-controlled, Parallel Group Study tsupportsStructured CT.gov primary outcome 'Percent Change From Baseline in LDL-C at 8 Weeks' (Atfer 8 weeks on study drug): drug -42% vs placebo +2% (Δ -44%).
  • trialNCT00631189 — Evaluation of the Efficacy and Safety of Rosuvastatin 5 mg Versus PravsupportsStructured CT.gov primary outcome 'Change in Low Density Lipoprotein Cholesterol (LDL-C) Level After 8 Weeks': drug arm -39.4% (vs an active comparator, not placebo).
  • trialNCT00639158 — A Multicenter, Randomized, Double-Blind, Prospective Study Comparing tsupportsStructured CT.gov secondary outcome 'Mean Percent Change in Very Low-Density Lipoprotein Cholesterol (VLDL-C) From Baseline to Final Visit' (Baseline to 12 weeks (final visit)): drug -57.8% vs placebo -41.1% (Δ -16.699999999999996%, p< 0.001).
  • trialNCT00172419 — Statin-Induced Vulnerable Plaque Regression After Atorvastatin TreatmeneutralNo posted results — existence/phase are not direction.
  • trialNCT00481364 — Atorvastatin Treatment to Attenuate the Progression of Cardiovascular neutralNo posted results — existence/phase are not direction.
  • paperMuscle microvascular dysfunction in central obesity is related to muscle insulin insensitivity but isupportsEfficacy on the claim outcome reported in the conclusion.
  • trialNCT00535405 — A Multicenter, Randomized, Double-Blind, Parallel, 12-Week Study to EvsupportsStructured CT.gov primary outcome 'Percent Change From Baseline in Low Density Lipoprotein (LDL-C) at Week 12': drug arm -39.5% (vs an active comparator, not placebo).
  • trialNCT00758004 — An Open Label, Randomized, Single Dose, Two-Way Crossover BioequivalenneutralNo posted results — existence/phase are not direction.
  • trialNCT00166036 — Effect of Statins on Oxidative Stress and Endothelial Progenitor CellsneutralResults posted but no readable target outcome — coverage only.
  • trialNCT00739999 — A 8-Week, Open-Label, Phase 1 Study To Evaluate Pharmacokinetics, PharsupportsStructured CT.gov secondary outcome 'Percent Change From Baseline in Pharmacodynamic Responses of Low-density Lipoprotein Cholesterol (LDL-C)': drug arm -36.27% (vs an active comparator, not placebo).
  • trialNCT02133534 — The Effect of Atorvastatin on Endothelial Cell Dysfunction in Chronic neutralResults posted but no readable target outcome — coverage only.
  • trialNCT00296400 — Randomised, Double-blind, 52-wk, Parallel-grp Multicentre, PIIb Study neutralResults posted but no readable target outcome — coverage only.
  • trialNCT00654095 — Open-label, Long-term Study of Coadministration of Ezetimibe and AtorvneutralResults posted but no readable target outcome — coverage only.
  • trialNCT00741715 — A Multicenter, Randomized, Placebo-controlled, "Factorial" Design, 12-neutralNo posted results — existence/phase are not direction.
  • trialNCT00683618 — A Randomised, Double-blind Trial to Compare the Efficacy of RosuvastatsupportsStructured CT.gov primary outcome 'Percentage Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) Concentration After 6 Weeks of Treatment Comparing Rosuvastatin 5mg With Atorvastatin 10mg': drug arm -38.67% (vs an active comparator, not placebo).
  • trialNCT01081548 — A Multi-center, Randomized, Open-labeled Clinical Trial to Evaluate EfneutralNo posted results — existence/phase are not direction.
  • trialNCT01285544 — Assessment of the Efficacy and Tolerability of Two Formulations of AtoneutralNo posted results — existence/phase are not direction.
  • trialNCT00728910 — Combined Effects of Non-statin Treatments on Apolipoprotein A-I Up-RegneutralResults posted but no readable target outcome — coverage only.
  • trialNCT01029522 — A Multi-center, Randomized, Double-blinded Equivalence Clinical Trial neutralNo posted results — existence/phase are not direction.
  • trialNCT01126684 — EFFECTS OF ATORVASTATIN ON BLOOD PRESSURE AND URINARY ALBUMIN EXCRETIOneutralNo posted results — existence/phase are not direction.
  • paperSafety and efficacy of ezetimibe added to atorvastatin versus up titration of atorvastatin to 40 mg neutralOn-topic, but the abstract's conclusion/results state no clear weight-loss outcome (aim, adjacent outcome, or mechanism only).
  • trialNCT00889226 — A Randomized, Open Label, Dose Titration Study to Evaluate the EfficacsupportsStructured CT.gov secondary outcome 'The Change of LDL-C': drug arm -70.9 mg/dl (vs an active comparator, not placebo).
  • trialNCT01497912 — Treatment Effects of Atorvastatin on Hemostasis and Skin MicrocirculatneutralNo posted results — existence/phase are not direction.
  • trialNCT00549926 — Yokohama Assessment of Fluvastatin, Pravastatin, Pitavastatin and AtorneutralNo posted results — existence/phase are not direction.
  • trialNCT00871351 — Ezetimibe Phase IV Clinical Study in Patients With HypercholesterolemisupportsStructured CT.gov primary outcome 'Percent Change in Low-Density Lipoprotein - Cholesterol (LDL-C) Values': drug arm -25.8% (vs an active comparator, not placebo).
  • trialNCT01768481 — Intervention précoce Sur Les Indices d'athérogénèse Des Adolescents à neutralNo posted results — existence/phase are not direction.
  • trialNCT00289900 — A Multicenter, Randomized, Double-Blind, Parallel Group, 12 Week StudysupportsStructured CT.gov primary outcome 'Percentage Change From Baseline in the LDL-C/HDL-C Ratio': drug arm -37.6% (vs an active comparator, not placebo).
  • trialNCT00782184 — A Randomized, Double-Blind, Active-Controlled Study of Patients With PsupportsStructured CT.gov primary outcome 'Percent Change From Baseline in Low Density Lipoprotein (LDL)-C': drug arm -26.81% (vs an active comparator, not placebo).
  • paperFunctional dilator capacity is independently associated with insulin sensitivity and age in central supportsEfficacy on the claim outcome reported in the conclusion.
  • trialNCT01166633 — A Randomized , Open Label, Dose Titration Study to Evaluate the EffectneutralNo posted results — existence/phase are not direction.
  • trialNCT00437892 — The Effect of Statins on D-dimer Levels in Patients With a Previous VeneutralNo posted results — existence/phase are not direction.
  • trialNCT01332747 — Clinical Study on Hyperlipidemia and Comparative Evaluation of EfficacneutralNo posted results — existence/phase are not direction.
  • trialNCT01105975 — A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in CombinatsupportsStructured CT.gov primary outcome 'Percent Change From Baseline to 12 Weeks Endpoint in Low Density Lipoprotein Cholesterol (LDL-C) With LY2484595 in Combination With Atorvastatin and Atorvastatin Monotherapy': drug arm -33.6% (vs an active comparator, not placebo).
  • trialNCT01218204 — A Study to Investigate the Safety, Tolerability, Pharmacokinetics and contradictsStructured CT.gov result — drug arm significantly did NOT reduce LDL cholesterol (+7.5%).
  • trialNCT01288469 — A Randomized, Double-blind, Parallel-group, Placebo-controlled, Fixed supportsStructured CT.gov primary outcome 'Percent Change From Baseline in Calculated LDL-C at Week 8 - On-treatment Analysis' (From Baseline to Week 8 (LOCF)): drug -66.2% vs placebo -17.3% (Δ -55.82%, p<0.0001).
  • paperAtorvastatin for prevention of atrial fibrillation recurrence following pulmonary vein isolation: a neutralOn-topic, but the abstract's conclusion/results state no clear weight-loss outcome (aim, adjacent outcome, or mechanism only).
  • paperPilot trial of bone-targeted therapy combining zoledronate with fluvastatin or atorvastatin for patineutralOn-topic, but the abstract's conclusion/results state no clear weight-loss outcome (aim, adjacent outcome, or mechanism only).
  • trialNCT01279590 — A Double-blind, Randomized, Placebo-controlled and Active-comparator-cneutralNo posted results — existence/phase are not direction.
  • trialNCT01288443 — A Randomized, Double-blind, Parallel-group, Placebo-controlled, MulticsupportsStructured CT.gov primary outcome 'Percent Change From Baseline in Calculated LDL-C at Week 12 - On-Treatment Analysis' (Baseline to Week 12 (LOCF)): drug -39.6% vs placebo -5.1% (Δ -34.5%, p<0.0001).
  • trialNCT00736463 — Effects of High Dose Simvastatin vs. Atorvastatin on Baseline LipoprotneutralNo posted results — existence/phase are not direction.
  • trialNCT00700037 — Effect of Atorvastatin Therapy on Fibrous Cap Thickness in Coronary AtneutralNo posted results — existence/phase are not direction.
  • trialNCT01236430 — A Study to Evaluate the Definitive Bioequivalence of SCH 900068 With MneutralNo posted results — existence/phase are not direction.
  • trialNCT01375075 — A Phase 2 Dose Response Study of LY2484595 in Japanese SubjectsneutralResults posted but no readable target outcome — coverage only.
  • paperRandomized controlled trial of atorvastatin in clinically isolated syndrome: the STAyCIS study.neutralOn-topic, but the abstract's conclusion/results state no clear weight-loss outcome (aim, adjacent outcome, or mechanism only).
  • trialNCT01370590 — A Randomized, Double-Blind, Active-Controlled, Multicenter, Crossover no_effectStructured CT.gov result (N=406) — no statistically significant effect on LDL cholesterol (drug -54%). Well-powered null: counts against the claim.
  • trialNCT01370603 — A Randomized, Double-Blind, Active-Controlled, Multicenter, Crossover no_effectStructured CT.gov result (N=328) — no statistically significant effect on LDL cholesterol (drug -58.9%). Well-powered null: counts against the claim.
  • trialNCT01386853 — A 12-week, Randomized, Multicenter, Double-blind, Active-controlled, NneutralNo posted results — existence/phase are not direction.
  • paperStudy design, rationale, and baseline characteristics: evaluation of fenofibric acid on carotid intineutralOn-topic, but the abstract's conclusion/results state no clear weight-loss outcome (aim, adjacent outcome, or mechanism only).
  • trialNCT00616772 — Evaluation of Choline Fenofibrate (ABT-335) on Carotid Intima-Media ThneutralResults posted but no readable target outcome — coverage only.
  • trialNCT00965055 — Atorvastatin vs. Atorvastatin/Ezetimibe in Patients With Hypo-responseneutralResults posted but no readable target outcome — coverage only.
  • trialNCT01154036 — A Randomized, Double-Blind, Active-Controlled, Multicenter Study of PasupportsStructured CT.gov primary outcome 'Percent Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C) (Phase I)': drug arm -24.8% (vs an active comparator, not placebo).
  • trialNCT01863225 — A Phase 2 Multiple-Dose Study to Characterize the Pharmacokinetics of neutralNo posted results — existence/phase are not direction.
  • trialNCT01842256 — A Randomized, Open-label, Single Dose, Two-treatment, Two-period, Two-neutralNo posted results — existence/phase are not direction.
  • trialNCT01023607 — Evaluation of Statin-induced Lipid-rich Plaque Progression by Optical neutralNo posted results — existence/phase are not direction.
  • trialNCT01779453 — A Placebo-Controlled, Randomized, Double-Blind, Parallel Group, Drug IneutralNo posted results — existence/phase are not direction.
  • trialNCT01779687 — Pharmacokinetic Drug Interaction Study Between Raltegravir and AtorvasneutralNo posted results — existence/phase are not direction.
  • trialNCT00827606 — A Three Year, Prospective, Open-label, Study To Evaluate Clinical EffisupportsStructured CT.gov primary outcome 'Percent Change From Baseline in LDL-C': drug arm -34.995% (vs an active comparator, not placebo).
  • trialNCT00861861 — Comparison of Pitavastatin With Atorvastatin in Increasing HDL-C and AneutralNo posted results — existence/phase are not direction.
  • trialNCT01660191 — A Study Comparing the Effects of Pitavastatin, Atorvastatin, and RosuvneutralResults posted but no readable target outcome — coverage only.
  • trialNCT01516879 — A Double-Blind, Randomized, Placebo-controlled, Multicenter Study to EsupportsStructured CT.gov primary outcome 'Percent Change From Baseline in LDL-C at Week 52' (Baseline and Week 52): drug -50.14% vs placebo +6.83% (Δ -56.97%, p<0.001).
  • trialNCT01763866 — A Double-blind, Randomized, Placebo and Ezetimibe Controlled, MulticenneutralResults posted but no readable target outcome — coverage only.
  • trialNCT01812707 — A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-contrsupportsStructured CT.gov primary outcome 'Percent Change From Baseline in Calculated LDL-C at Week 12 - On-Treatment Analysis' (Baseline to Week 12 (LOCF)): drug -54.8% vs placebo -2.7% (Δ -52.099999999999994%, p<0.0001).
  • trialNCT02094313 — Effects of Decrease in Cholesterol Levels Induced by a Statin on SpermneutralNo posted results — existence/phase are not direction.
  • trialNCT02342015 — Effect of Atorvastatin on OPG/RANK/RANKL Expression in Immune Cells anneutralResults posted but no readable target outcome — coverage only.
  • trialNCT01730040 — A Randomized, Double-Blind Study of the Efficacy and Safety of AlirocuneutralResults posted but no readable target outcome — coverage only.
  • trialNCT02066207 — Open-label, Randomized, Multiple-dose, Crossover Study to Evaluate theneutralNo posted results — existence/phase are not direction.
  • trialNCT01544309 — Study on Effect of Highly Potent Statins on Lipid Lowering Effect and supportsStructured CT.gov secondary outcome 'Percent Changes in Lipids (LDL-C, HDL-C, TC, TG, Non-HDL-C/HDL-C Ratio, and FFA)': drug arm -36.6% (vs an active comparator, not placebo).
  • trialNCT01953328 — A Double-blind, Randomized, Placebo-controlled, Multicenter Study to EsupportsStructured CT.gov primary outcome 'Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at the Mean of Weeks 10 and 12' (Baseline and Weeks 10 and 12): drug -73.7% vs placebo +0.27% (Δ -73.97%, p<0.001).
  • trialNCT01970215 — A Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, ParallelneutralNo posted results — existence/phase are not direction.
  • trialNCT01974297 — Comparison of the Efficacy and AtorVastatin 20mg mOnotherapy Versus ConeutralNo posted results — existence/phase are not direction.
  • trialNCT01448174 — Salusin-alpha - a New Factor in the Pathogenesis of Lipid AbnormalitieneutralNo posted results — existence/phase are not direction.
  • trialNCT01236365 — Statins in Children With Type 1 Diabetes: Effects on Metabolism, InflaneutralResults posted but no readable target outcome — coverage only.
  • trialNCT01541943 — A Phase 3, Randomized, Double- Blind, Multi-center, Double Dummy, ClinneutralNo posted results — existence/phase are not direction.
  • paperA randomized, double blind, placebo-controlled pilot trial of the safety and efficacy of atorvastatineutralOn-topic, but the abstract's conclusion/results state no clear weight-loss outcome (aim, adjacent outcome, or mechanism only).
  • trialNCT00663234 — Phase I/II Safety and Efficacy Investigation of Atorvastatin for TreatsupportsStructured CT.gov primary outcome 'Percent Change in LDL Cholesterol (LDL-C) From Study Entry': drug arm -30.3% (single-arm, no control) — only N=28, treated as weak.
  • trialNCT02035215 — Efficacy and Safety of Co-administration of Omacor Plus Atorvastatin CneutralNo posted results — existence/phase are not direction.
  • paperEffects of statin therapy on coronary artery plaque volume and high-risk plaque morphology in HIV-inneutralOn-topic, but the abstract's conclusion/results state no clear weight-loss outcome (aim, adjacent outcome, or mechanism only).
  • trialNCT02189837 — Double-blind, Randomized, Placebo-controlled, Single Site Study to EvacontradictsStructured CT.gov result — drug arm significantly did NOT reduce LDL cholesterol (+310.48%, p<0.001).
  • trialNCT02374047 — A 2-Part, Phase 1, Single and Multiple Ascending Dose Study to Assess neutralNo posted results — existence/phase are not direction.
  • trialNCT02566187 — A Study to Compare the Pharmacokinetics of Fimasartan/Atorvastatin ComneutralNo posted results — existence/phase are not direction.
  • trialNCT02135029 — A Phase 3, Double-blind, Double-dummy, Randomized, Placebo And Active neutralResults posted but no readable target outcome — coverage only.
  • trialNCT02260648 — A Double-Blind Efficacy and Safety Study of Evacetrapib in CombinationsupportsStructured CT.gov primary outcome 'Percent Change From Baseline to Week 12 in Low-Density Lipoprotein Cholesterol (LDL-C) Measured by Beta Quantification' (Baseline, Week 12): drug -26.37% vs placebo -3.75% (Δ -22.62%).
  • trialNCT01322711 — Effects on Oxidative Stress, Coagulation, Platelet Activation and InflneutralNo posted results — existence/phase are not direction.
  • trialNCT02227784 — The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High neutralResults posted but no readable target outcome — coverage only.
  • trialNCT02942602 — Effect of Lipid Modifying Drugs on HDL Function in Patients With HyperneutralNo posted results — existence/phase are not direction.
  • trialNCT02550288 — A Phase III, Randomized, Active Comparator-controlled Clinical Trial tsupportsStructured CT.gov primary outcome 'Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Week 12' (Baseline and Week 12): drug -59.2% vs placebo -19.3% (Δ -39.9%, p<0.001).
  • trialNCT02608697 — A Randomized, Double-Blind, Placebo-Controlled Study to Assess the SafneutralNo posted results — existence/phase are not direction.
  • trialNCT02659397 — A Study to Assess the Pharmacokinetics, Pharmacodynamics and Safety ofneutralNo posted results — existence/phase are not direction.
  • trialNCT01956201 — Efficacy and Safety of Fenofibrate Added on to Atorvastatin Compared WneutralNo posted results — existence/phase are not direction.
  • trialNCT01720719 — An Randomized Open Label Trial on the Impact of 24 Weeks of AtorvastatneutralNo posted results — existence/phase are not direction.
  • trialNCT02714569 — A Randomized, Double-Blind, Placebo-Controlled, Single and Multiple OrneutralResults posted but no readable target outcome — coverage only.
  • trialNCT01709513 — A Randomized, Double-Blind, Double-Dummy, Active-Controlled Study to EneutralResults posted but no readable target outcome — coverage only.
  • trialNCT02979704 — Randomized. Open Label Trial of Comparison Between Rosuvastatin and AtneutralNo posted results — existence/phase are not direction.
  • trialNCT03051100 — A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study tsupportsStructured CT.gov primary outcome 'Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Week 6' (Baseline; Week 6): drug -63.6% vs placebo -3.1% (Δ -60.5%, p<0.001).
  • trialNCT01984424 — A Double-blind, Randomized, Multicenter Study to Evaluate the Safety ano_effectStructured CT.gov pre-specified outcome 'Percent Change From Baseline in Very Low-density Lipoprotein' (N=511) — no significant effect on LDL cholesterol (Δ -4.65 [-12.25–2.94], p=0.37). Well-powered null: counts against the claim.
  • trialNCT02662569 — A Double-blind, Randomized, Placebo-controlled, Multicenter Study to EsupportsStructured CT.gov primary outcome 'Percent Change From Baseline in LDL-C at the Mean of Weeks 10 and 12' (Baseline and weeks 10 and 12): drug -65.35% vs placebo +4.94% (Δ -70.29%, p<0.0001).
  • trialNCT02364258 — Pharmacokinetics of Rosuvastatin and Atorvastatin in Pediatric DyslipineutralNo posted results — existence/phase are not direction.
  • trialNCT02584504 — A Randomized, Double-blind, Placebo-controlled, Parallel Group Study tsupportsStructured CT.gov primary outcome 'Percent Change From Baseline in Calculated LDL-C at Week 12- Intent to Treat (ITT) Analysis' (From Baseline to Week 12): drug -70.1% vs placebo -43.8% (Δ -26.3%).
  • trialNCT02977065 — Multicenter, Parallel-group, Double-blind, Randomized, Active-controllneutralNo posted results — existence/phase are not direction.
  • trialNCT02984982 — A Randomized, Open-label, Blinded Intravascular Ultrasound Analysis, PneutralStructured CT.gov result — no clinically-meaningful LDL cholesterol change in the drug arm (-7.57%).
  • trialNCT02715726 — A Randomized, Double-blind, Parallel Group Study to Evaluate the EfficneutralResults posted but no readable target outcome — coverage only.
  • trialNCT03415178 — A Multicenter, Randomized, Open-label, Parallel-group Usability Study neutralResults posted but no readable target outcome — coverage only.
  • trialNCT03433196 — Randomized,Double Blind,Double Dummy, Multi-center Study of Efficacy aneutralNo posted results — existence/phase are not direction.
  • trialNCT02476006 — A Multi-country, Multicenter, Single-arm, Open-label Study to DocumentsupportsStructured CT.gov secondary outcome 'Percent Change From Baseline in Calculated Low Density Lipoprotein Cholesterol (LDL-C) at Week 12': drug arm -54.84% (single-arm, no control).
  • trialNCT03338426 — A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate tneutralNo posted results — existence/phase are not direction.
  • trialNCT03464682 — Multi-center,Randomized,Double Blind, Double Dummy,Placebo Controlled,neutralNo posted results — existence/phase are not direction.
  • trialNCT03604471 — Lipid-lowering Therapy IndividualizationneutralNo posted results — existence/phase are not direction.
  • trialNCT03696940 — Estudio clínico Fase III Para Evaluar la Eficacia terapéutica en PacieneutralNo posted results — existence/phase are not direction.
  • trialNCT03784703 — Efficacy of Atorvastatin Versus Rosuvastatin on LV Function and InflamneutralNo posted results — existence/phase are not direction.
  • trialNCT03510715 — An Open-Label Study to Evaluate the Efficacy and Safety of Alirocumab neutralStructured CT.gov result — no clinically-meaningful LDL cholesterol change in the drug arm (-4.1%).
  • trialNCT03611010 — Phase II, Dose-ranging Study to Evaluate the Efficacy Dose Response ancontradictsStructured CT.gov result — drug arm significantly did NOT reduce LDL cholesterol (+12.36 mg/dL).
  • trialNCT02437084 — Relationship Between Insulin Resistance and Statin Induced Type 2 DiabneutralResults posted but no readable target outcome — coverage only.
  • trialNCT02668016 — Self-Assessment Method for Statin Side-effects Or NoceboneutralResults posted but no readable target outcome — coverage only.
  • trialNCT03768427 — A Phase 3 Randomized, Active-comparator-controlled Clinical Study to EneutralResults posted but no readable target outcome — coverage only.
  • trialNCT03110848 — A Phase II, Open-labeled, Ophthalmological External Investigator-blindneutralNo posted results — existence/phase are not direction.
  • trialNCT03750760 — Early Alirocumab to Reduce LDL-C in Myocardial InfarctionneutralNo posted results — existence/phase are not direction.
  • trialNCT03418974 — Safety and Efficacy of Statins for Chinese Patients With Dyslipidemia:neutralNo posted results — existence/phase are not direction.
  • trialNCT03906539 — Effect of Virgin Coconut Oil (VCO) on Cardiometabolic Parameters in PaneutralNo posted results — existence/phase are not direction.
  • trialNCT04591808 — Efficacy and Safety of Atorvastatin + Perindopril Fixed-Dose CombinatineutralNo posted results — existence/phase are not direction.
  • trialNCT04882293 — Confirmatory Study of the Efficacy and Safety of the Fixed-dose CombinneutralNo posted results — existence/phase are not direction.
  • trialNCT03510884 — A Randomized, Double-Blind, Placebo-Controlled Study Followed by an OpneutralResults posted but no readable target outcome — coverage only.
  • trialNCT05806723 — Effects of High Intensity Statin Therapy on Steroid Hormones and VitamneutralNo posted results — existence/phase are not direction.
  • trialNCT05970679 — A Randomized, Double Blind, Parallel, Multi-center, Phase 3 Clinical TneutralNo posted results — existence/phase are not direction.
  • trialNCT04922424 — Mechanisms and Interventions to Address Cardiovascular Risk of Gender-neutralNo posted results — existence/phase are not direction.
  • trialNCT05790499 — Continuous Atorvastatin Therapy Compared With Intermittent AtorvastatineutralNo posted results — existence/phase are not direction.
  • trialNCT06239714 — A Phase 1, Randomized, Double-Blind, Placebo-Controlled, SAD and MAD SneutralNo posted results — existence/phase are not direction.
  • trialNCT06784557 — Gut Microbiota Alteration With Atorvastatin/Ezetimibe Combination in PneutralNo posted results — existence/phase are not direction.
  • trialNCT07497776 — Atorvastatin Therapy in the Treatment of Dyslipidemia in Children WithneutralNo posted results — existence/phase are not direction.
  • trialNCT06789432 — Efficacy and Safety of Atorvastatin and Ezetimibe (10/10mg) Fixed DoseneutralNo posted results — existence/phase are not direction.
  • trialNCT06841536 — Combined Effects of Statins and Exercise on Physiological Health MarkeneutralNo posted results — existence/phase are not direction.
  • trialNCT02726555 — Comparison Between Combined Therapy With Red Yeast Rice and Low-dose SneutralNo posted results — existence/phase are not direction.
View methodology and known limitations
Engine methodology v1.7.0. Methodology-version changes are recorded separately from new evidence; a change in engine version reinterprets existing evidence and is not a new scientific discovery.
  • Engine constants are calibrated against a small anchor set — coarse, not authoritative.
  • Evidence is skewed toward the drug's sponsor; genuinely independent replication is the honest ceiling.
  • Paper direction is extracted from abstracts; the hedged tail stays neutral (coverage, not confidence).
  • Regulatory approval is tracked on a separate axis and never inflates evidential confidence.
Computed 2026-08-05 · not medical advice.